ARS pharmaceuticals is developing an intranasal epinephrine spray for patients at-risk of severe allergic reactions to food, medications and insect bites that could lead to anaphylaxis.
SPRY
6.66 as of 3/27/23
| Date | Funding Round | Funding Raised | Price per Share | IPO Valuation |
|---|---|---|---|---|
| 8/31/2021 | Series D | $310.11MM | $XXX.XX | $XXX.XX |
| 9/14/2018 | Series C | $113.71MM | $XXX.XX | $XXX.XX |
| 4/30/2018 | Series B | $44.3MM | $XXX.XX | $XXX.XX |
| 4/30/2016 | Series A | $1.13MM | $XXX.XX | $XXX.XX |
